ARTICLE SUMMARY:
Advanced robotic systems like Intuitive Surgical's fifth-generation da Vinci and HistoSonics’ Edison Histotripsy System have the potential to enhance surgical precision, efficiency, and collaboration, ultimately leading to improved patient experiences.
The surgical robotics market is currently valued at more than $8 billion, growing at a double-digit rate, with sales expected to more than triple by 2032, according to the investment firm Gabelli Group. Robotics pioneer
Intuitive Surgical continues to be the dominant player with greater than 80% market share, nearly 10,000
da Vinci systems placed, and revenue growth in the mid to high teens, more than 20 years after it introduced the
da Vinci robot (
see Figure 1). Opportunities for competition remain wide, however, as only 2% of surgeries use robotics. (
See “When Will the Future Arrive?” MedTech Strategist, J
anuary 14, 2025, and
“NASS 2024: Industry Is Healthy, Surgery Profession Is Under Strain,” MedTech Strategist,
October 24, 2024.)
Dozens of companies are developing soft-tissue systems with advanced features, specificity, and applications, increasingly augmented by artificial intelligence. A recent panel organized by Gabelli Group and the Columbia Business School highlighted several of these achievements, focusing on Intuitive’s fifth-generation
da Vinci and
HistoSonics’ noninvasive
Edison Histotripsy System.
